The p53-MDM2/MDMX axis - A chemotype perspective

被引：58

作者：

Khoury, Kareem ^{[1
]}

Popowicz, Grzegorz M. ^{[2
]}

Holak, Tad A. ^{[2
]}

Doemling, Alexander ^{[1
]}

机构：

[1] Univ Pittsburgh, Dept Pharmaceut Sci, Drug Discovery Inst, Pittsburgh, PA 15260 USA

[2] Max Planck Inst Biochem, D-8000 Munich, Germany

来源：

MEDCHEMCOMM | 2011年 / 2卷 / 04期

关键词：

PROTEIN-PROTEIN INTERACTION; SUPPRESSOR TRANSACTIVATION DOMAIN; SMALL-MOLECULE ANTAGONISTS; STRUCTURE-BASED DESIGN; WILD-TYPE P53; MDM2; INHIBITORS; CANCER-THERAPY; IN-VIVO; IDENTIFY DISRUPTORS; HDM2; ANTAGONISTS;

D O I：

10.1039/c0md00248h

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The protein-protein interaction (PPI) of the tumor suppressor p53 and its negative regulator MDM2 consists of the most intense studied PPI with a group of small molecular weight antagonists described and many more disclosed in patent literature. Due to the A-level structural insight into p53 interaction with MDM2 there is a reasonable understanding of the requirements of the molecules to bind. In contrast and despite the very close homology and 3-D similarity no potent MDMX antagonist has been disclosed up to date. The current review summarizes the different disclosed chemotypes for MDM2 including a discussion of the cocrystal structures. Structures and approaches to reconstitute functional p53 from mutated p53 are presented. Finally new screening methods and recent biotech deals based on p53 are discussed.

引用

页码：246 / 260

页数：15

共 50 条

[31] Sulfonamide derivatives of cis-imidazolines as potent p53-MDM2/MDMX protein-protein interaction inhibitors
Bazanov, Daniil R.
Pervushin, Nikolay, V
Savin, Egor, V
Tsymliakov, Michael D.
Maksutova, Anita, I
Sosonyuk, Sergey E.
Kopeina, Gelina S.
Lozinskaya, Natalia A.
MEDICINAL CHEMISTRY RESEARCH, 2021, 30 (12) : 2216 - 2227
[32] Profiling inhibitors of MDM2: p53 and MDMX: p53 in relation to MDMX protein levels
Tudhope, Sue
Zhao, Yan
Wittner, Anita
Wilmore, Elaine
Bertoli, Annalisa
Adhikari, Santosh
Harnor, Suzannah J.
Del Bello, Fabio
Piergentili, Alessandro
Lunec, John
Hardcastle, Ian R.
Griffin, Roger J.
Golding, Bernard R.
Cano, Celine
Newell, David R.
Wedge, Stephen R.
CANCER RESEARCH, 2014, 74 (19)
[33] The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy
Liu, Yao
Wang, Xiaohui
Wang, Guan
Yang, Yushang
Yuan, Yong
Ouyang, Liang
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 176 : 92 - 104
[34] A dynamic role of HAUSP in the p53-Mdm2 pathway
Li, MY
Brooks, CL
Kon, N
Gu, W
MOLECULAR CELL, 2004, 13 (06) : 879 - 886
[35] Explaining oscillations and variability in the p53-Mdm2 system
Proctor, Carole J.
Gray, Douglas A.
BMC SYSTEMS BIOLOGY, 2008, 2
[36] Synthesis and Biological Evaluation of Novel Synthetic Indolone Derivatives as Anti-Tumor Agents Targeting p53-MDM2 and p53-MDMX
Wang, Yali
Ji, Bo
Cheng, Zhongshui
Zhang, Lianghui
Cheng, Yingying
Li, Yingying
Ren, Jin
Liu, Wenbo
Ma, Yuanyuan
MOLECULES, 2022, 27 (12):
[37] Sulfonamide derivatives of cis-imidazolines as potent p53-MDM2/MDMX protein-protein interaction inhibitors
Daniil R. Bazanov
Nikolay V. Pervushin
Egor V. Savin
Michael D. Tsymliakov
Anita I. Maksutova
Sergey E. Sosonyuk
Gelina S. Kopeina
Natalia A. Lozinskaya
Medicinal Chemistry Research, 2021, 30 : 2216 - 2227
[38] Non-naturally Occurring Helical Molecules Can Interfere with p53-MDM2 and p53-MDMX Protein-Protein Interactions
Su, Aoze
Wang, Siyuan
Sada, Akane
Otani, Yuko
Zhai, Luhan
Liu, Xin
Sayama, Misa
Ohki, Rieko
Ohwada, Tomohiko
CHEMICAL & PHARMACEUTICAL BULLETIN, 2019, 67 (10) : 1139 - 1143
[39] Molecular simulation of the p53-MDM2 binding interface
Pantelopulos, George A.
Voelz, Vincent A.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
[40] A dynamic p53-mdm2 model with distributed delay
Horhat, Raluca
Horhat, Raul Florin
10TH INTERNATIONAL CONFERENCE ON MATHEMATICAL PROBLEMS IN ENGINEERING, AEROSPACE AND SCIENCES (ICNPAA 2014), 2014, 1637 : 413 - 421

← 1 2 3 4 5 →